

ASX Announcement

Medibio Limited – 10th August 2020



Medibio granted US Patent for Monitoring Stress Conditions Using Heartrate

Melbourne, Australia and Minneapolis, MN – 10th August 2020: Medibio Limited (Medibio or the Company) (ASX: MEB) (OTCPINK: MDBIF), a mental health technology company announces that the US Patent and Trademark Office has granted it a patent entitled “Method and System for Monitoring Stress Conditions.”

The patent relates to a software method, using machine learning, for monitoring stress conditions by analysing heartrate collected during sleep, including a pre-sleep period, a sleep period and a post-sleep period.

The patent will play an important part in protecting Medibio’s corporate product offering, ilumen™; and its consumer app currently under development, complementing its existing USA Patent relating to a method of assessing mental state such as depression, by analysing heartrate collected during sleep, and strengthening its intellectual property protection and competitive advantage in the US market.

Medibio is in the process of reviewing the scope and breadth of the protection these patents afford it and will advise the market as appropriate and in accordance with its continuous disclosure obligations.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

WE Communications

WE-AUMedibio@we-worldwide.com

T: +61 2 9237 2805